玻璃体腔注射雷珠单抗治疗新生血管性眼病的临床疗效及安全性分析

doi:10.3969/j.issn.1006-6233.2018.11.032

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1254 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the clinical effect and safety of intraventricular injection with lebezumab in the treatment neonatal vascular eye disease. Methods: 78 patients with choroidal neovascularization admitted to our hospital from February 2016 to December 2017 were randomly divided into control group and study group, 39 cases in each group. The control group was treated with vitrified photodynamic therapy (PDT), and the study group was treated with intravitreal injection of razomab. The clinical efficacy, best corrected visual acuity, macular foveal retinal thickness (CRT), and adverse reactions were compared between the two groups. Results: The effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). There was no difference in the best corrected visual acuity and CRT between the two groups before treatment (P>0.05). The best corrected visual acuity and CRT of the two groups increased in 1 month and decreased in 6 months after treatment, and the change was more obvious in the study group. There were significant differences in the best corrected visual acuity and CRT between the two groups in 1 month and 6 months after treatment (P<0.05). The incidence of adverse reactions in the control group and the study group were 10.26% (4/39) and 12.82% (5/39), respectively. There was no significant difference between the two groups (P > 0.05). Conclusion: Intravitreal injection of razomab in the treatment of choroidal neovascularization has a prominent effect. And it can improve visual acuity, improve retinal edema, worthy of clinical promotion.

Key words： Neonatal vascular eye disease Vitreous cavity injection Thunderball single reactance Security

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Jinshou
	ZHANG Rong
	QI En

Cite this article:

YANG Jinshou,ZHANG Rong,QI En. Clinical Study and Safety of Intraventricular Injection with Lebezumab in the treatment Neonatal Vascular Eye Disease[J]. HeBei Med, 2018, 24(11): 1892-1894.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.11.032 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I11/1892

[1] Miere A , Querques G , Semoun O , et al. Optical coherence tomography angiography changes in early type 3 neovascularization after anti-vascular endothelial growth factor treatment[J]. Retina (Philadelphia, Pa.),2017,37 (10 ):1873~1879.
[2] Andreanos KD , Rotsos T , Koutsandrea C , et al. Detection of nonexudative choroidal neovascularization secondary to angioid streaks using optical coherence tomography angiography[J]. European journal of ophthalmology,2017,27 (5 ):e140~e143.
[3] 张颖,李云琴.脉络膜新生血管治疗的新进展[J].西部医学,2015,27(11):1752~1753.
[4] 陈彦霓,陈子林.抗VEGF药物治疗新生血管性眼病的现状与展望[J].医学综述,2016,22(8):1550~1553.
[5] 党陈晔,龚政军.雷珠单抗治疗新生血管性眼病的临床疗效观察[J].实用医院临床杂志,2016,13(6):73~76.
[6] 戚沆,陈长征,易佐慧子,等.玻璃体腔重复注射雷珠单抗对脉络膜新生血管患眼脉络膜厚度的影响[J].中华眼底病杂志,2015,31(1):31~35.
[7] 王雨生.脉络膜新生血管性疾病[M].人民卫生出版社,2007.37~38.
[8] Crespogarcia S, Corkhill C, Roubeix C, et al. Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization.[J]. Invest Ophthalmol Vis Sci, 2017, 58(12):4997~5006.
[9] 苏延梅.光动力疗法联合Lucentis玻璃体腔注射治疗脉络膜新生血管疾病的疗效评估[J].海南医学院学报,2016,22(5):509~511.
[10] 唐坤,黄一飞.脉络膜新生血管的临床治疗研究进展[J].中国激光医学杂志,2015,24(2):101~108.
[11] 刘洋,黎蕾.光动力疗法联合抗血管内皮生长因子药物治疗脉络膜新生血管的进展[J].国际眼科杂志,2016,16(11):2048~2052.
[12] 黄延,张晓峰.玻璃体腔注射抗VEGF药物治疗脉络膜新生血管疾病疗效分析[J].临床眼科杂志,2016,24(2):134~137.
[13] 曹明芳,江蕊,张文贤,等.脉络膜新生血管模型大鼠视网膜核转录因子-κBp65、血管内皮生长因子和碱性成纤维细胞生长因子表达的变化[J].眼科新进展,2016,36(7):615~617.
[14] Traversi C, Nuti E, Marigliani D, et al. Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization[J]. Graefes Archive for Clinical & Experimental Ophthalmology, 2015, 253(4):511~517.